IRAK4 and myeloid neoplasm: The central role of IRAK-4 in aberrant TLR/innate immune signaling in B-cell NHL and myeloid malignancies makes emavusertib a promising therapeutic agent that can curtail pro-tumoral inflammation and synergize with other therapies to enhance malignant cell apoptosis.